5979 |
RET PROTO-ONCOGENE |
RET |
CDHF12 |
CDHR16 |
HSCR1 |
MEN2A |
MEN2B |
MTC1 |
PTC |
RET-ELE1 |
164761 |
9967 |
ENSG00000165731 |
OTTHUMG00000018024 |
P07949 |
RET51 |
RET_HUMAN |
PROTO-ONCOGENE TYROSINE-PROTEIN KINASE RECEPTOR RET PRECURSOR (EC 2.7.1.112) (C-RET). [SOURCE:UNIPROT/SWISSPROT;ACC:P07949] |
SOLUBLE RET KINASE FRAGMENT |
42 |
PROTO-ONCOGENE TYROSINE-PROTEIN KINASE RECEPTOR RET |
Proto-oncogene c-Ret |
Cadherin family member 12 |
Extracellular cell-membrane anchored RET cadherin 120 kDa fragment |
PA34335 |
T60631 |
Target Class | Receptors |
Target Subclass | EC:2.7.10.1 |
Initial Gene Query | RET |
Counted Citations from 1950-2000 | 2777 |
Human Readable Name | DRUGGABLE GENOME |
Uniprot Status | Swiss-Prot |
Interpro Type | Domain |
Interpro Short Name | Ser-Thr/Tyr_kinase_cat_dom |
Interpro Name | Serine-threonine/tyrosine-protein kinase catalytic domain |
Uniprot Evidence | 1: Evidence at protein level |
Human Readable Name | KINASE |
Interpro Acc | IPR001245 |
Target Subclass | Kinase |
Target Main Class | Receptors |
Target Subclass | Other |
Transmembrane Helix Count | 1 |
Gene Biotype | PROTEIN_CODING |
KINASE |
TYROSINE KINASE |
DRUG RESISTANCE |
DRUGGABLE GENOME |
CLINICALLY ACTIONABLE |
antagonist (inhibitory) |
inhibitor (inhibitory) |
Notes | |
Indication/Tumor Type | thyroid medullary carcinoma |
Response Type | sensitive |
inhibitor (inhibitory) |
Trial Name | Zactima |
Novel drug target | Established target |
Notes |
inhibitor (inhibitory) |
combination therapy | Cetuximab + Sunitinib |
Indication/Tumor Type | olfactory neuroblastoma |
Response Type | sensitive |
inhibitor (inhibitory) |
Evidence Type | Actionable |
Approval Status | Preclinical - Cell line xenograft |
Response Type | predicted – sensitive |
inhibitor (inhibitory) |
Mechanism of Interaction | Tyrosine-protein kinase receptor RET inhibitor |
Direct Interaction | yes |
inhibitor (inhibitory) |
Notes | |
Trial Name | MP-470 |
Novel drug target | Established target |
inhibitor (inhibitory) |
Notes | |
Mechanism of Interaction | Tyrosine-protein kinase receptor RET inhibitor |
Direct Interaction | yes |
inhibitor (inhibitory) |
Indication/Tumor Type | thyroid medullary carcinoma |
Response Type | predicted – sensitive |
Approval Status | Phase II |
inhibitor (inhibitory) |
Mechanism of Interaction | Tyrosine-protein kinase receptor RET inhibitor |
Direct Interaction | yes |
inhibitor (inhibitory) |
Mechanism of Interaction | Tyrosine-protein kinase receptor RET inhibitor |
Direct Interaction | yes |
inhibitor (inhibitory) |
Mechanism of Interaction | Tyrosine-protein kinase receptor RET inhibitor |
Direct Interaction | yes |
inhibitor (inhibitory) |
Direct Interaction | yes |
Mechanism of Interaction | Tyrosine-protein kinase receptor RET inhibitor |
inhibitor (inhibitory) |
Notes |
inhibitor (inhibitory) |
Mechanism of Interaction | Tyrosine-protein kinase receptor RET inhibitor |
Direct Interaction | yes |
inhibitor (inhibitory) |
Mechanism of Interaction | Tyrosine-protein kinase receptor RET inhibitor |
Direct Interaction | yes |
inhibitor (inhibitory) |
Trial Name | imatinib mesylate, STI 571,Gleevec, Glivec |
Novel drug target | Established target |
n/a |
Indication/Tumor Type | Advanced Solid Tumor |
Response Type | sensitive |
Approval Status | Phase I |
n/a |
Trial Name | ENMD-2076 |
Novel drug target | Established target |
inhibitor (inhibitory) |
Trial Name | ABT-869, Linifanib |
Novel drug target | Established target |
inhibitor (inhibitory) |
RET | Ensembl Gene Name |
Gene Biotype | PROTEIN_CODING |
5979 | Entrez Gene Id |
RET | Gene Symbol |
ENSG00000165731 | Ensembl Gene Id |
Target Subclass | Kinase |
Target Main Class | Receptors |
Target Subclass | Other |
RET | Gene Symbol |
Target Class | Receptors |
Target Subclass | EC:2.7.10.1 |
PROTO-ONCOGENE TYROSINE-PROTEIN KINASE RECEPTOR RET PRECURSOR (EC 2.7.1.112) (C-RET). [SOURCE:UNIPROT/SWISSPROT;ACC:P07949] | Description |
RET | Display Id |
ENSG00000165731 | Ensembl Gene Id |
Human Readable Name | DRUGGABLE GENOME |
DRUGGABLE GENOME |
5979 | Entrez Gene ID |
Initial Gene Query | RET |
Counted Citations from 1950-2000 | 2777 |
KINASE |
RET_HUMAN | Uniprot Id |
SOLUBLE RET KINASE FRAGMENT | Uniprot Protein Name |
ENSG00000165731 | Ensembl Gene Id |
Uniprot Status | Swiss-Prot |
Interpro Type | Domain |
Interpro Short Name | Ser-Thr/Tyr_kinase_cat_dom |
KINASE, DRUGGABLE GENOME |
5979 | CKB Entrez Id |
RET | CKB Gene Synonym |
CDHF12 | CKB Gene Synonym |
PA34335 | PharmGKB ID |
5979 | Entrez Gene ID |
42 | CIViC Gene ID |
DRUG RESISTANCE |
RET | Gene Symbol |
CDHR16 | GENE_SYMBOL |
PTC | GENE_SYMBOL |
RET51 | GENE_SYMBOL |
ENSG00000165731 | Gene Symbol |
RET | Ensembl Id |
DRUGGABLE GENOME |
5979 | Entrez Gene Id |
RET | MyCancerGenome Gene Symbol |
RET | MyCancerGenome Reported Gene Name |
5979 | OncoKB Entrez Id |
MTC1 | OncoKB Gene Synonym |
CDHF12 | OncoKB Gene Synonym |
CDHF12 | GO Gene Synonym |
CDHR16 | GO Gene Synonym |
PTC | GO Gene Synonym |
TYROSINE KINASE |
RET | Gene Symbol |
CLINICALLY ACTIONABLE |
5979 | Gene ID |
CDHF12 | dGene Synonym |
CDHR16 | dGene Synonym |
KINASE, TYROSINE KINASE |
RET | TTD Gene Abbreviation |
T60631 | TTD Target ID |
Proto-oncogene tyrosine-protein kinase receptor Ret | Gene Name |
P07949 | UniProt ID |
KINASE |
CLINICALLY ACTIONABLE |
CLINICALLY ACTIONABLE |
CLINICALLY ACTIONABLE |
CLINICALLY ACTIONABLE |